Related Experiment Video
Updated: May 5, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
A history of devices as an alternative to heart transplantation
Garrick C Stewart1, Mandeep R Mehra
1Center for Advanced Heart Disease, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Abstract:
The rapid evolution of mechanical circulatory support (MCS) has extended survival and improved quality of life for patients suffering from the most advanced heart failure (HF). Survival at one year after placement of a left ventricular assist device exceeds 80%. MCS and transplant have developed in counterpoint to each other. Patients with HF now have a meaningful option for lifelong support even if they are not candidates for heart transplant. As the profiles of MCS recipients change and the next generation of devices emerges, new challenges and opportunities await physicians caring for patients with cardiac failure.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy

